TOP - August 2019, Vol 12, No 3

This section provides a brief overview of new cancer drugs or new indications approved by the FDA between June 10 and July 3, 2019.

Skin cancer is the most frequently diagnosed malignancy in the United States. Although invasive melanoma comprises approximately 1% of skin cancers, it is the cause of a vast majority of skin cancer–related deaths. The following provides helpful information related to this malignancy.

Genetic alterations in molecular pathways are involved in tumor development, survival, and progression.

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a patient’s own genetically modified T-cells to fight cancer.